Search Medical Condition
Please enter condition
Please choose location

Hilliard, Ohio Clinical Trials

A listing of Hilliard, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (478) clinical trials

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

UPGRADE aims to see whether data from Pharmacogenomic Testing (PGx) can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug reactions, hospitalizations and emergency department visits. The way an individual processes a drug is in part determined by their genes, and ...

Phase N/A

0.0 miles

Learn More »

A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated

This is an open-label, non‐randomized, multicenter Phase 1/2 study of MEDI4736 in subjects with recurrent, platinum-resistant ovarian cancer, scheduled to receive Pegylated Liposomal Doxorubicin (PLD). Subjects will be treated during each 28-day cycle according to the treatment schedule.

Phase

0.0 miles

Learn More »

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD or Pembrolizumab in Adults With FRa + Adv. EOC Primary Peritoneal Fallopian Tube or Endometrial Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

0.0 miles

Learn More »

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The ...

Phase

0.0 miles

Learn More »

Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer

Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their ...

Phase

1.06 miles

Learn More »

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

The primary objective of the study is to evaluate the time to resolution of influenza symptoms in adults with acute uncomplicated seasonal influenza A following administration of VX-787, with and without concomitant oseltamivir.

Phase

1.06 miles

Learn More »

Saline-Controlled Study of nSTRIDE APS for Knee Osteoarthritis

A double-blind, multicenter, randomized, saline-controlled trial (RCT) that will evaluate the efficacy of a single dose of Autologous Protein Solution (APS) in patients with symptomatic osteoarthritis (OA) of the knee who have not been able to get satisfactory pain relief with prior treatment.

Phase N/A

3.28 miles

Learn More »

NOVOCART 3D for Treatment of Articular Cartilage of the Knee

Subjects with articular knee defects will be randomized to receive either Microfracture or NOVOCART 3D. Subjects will be followed for five years in total and will be evaluated for safety and efficacy.

Phase

3.28 miles

Learn More »

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

Phase

3.28 miles

Learn More »

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The ...

Phase

3.28 miles

Learn More »